Drugmaker Actavis said on Tuesday that it will buy Forest Laboratories for approximately $25 billion. The deal stands to give Actavis a broader portfolio of pharmaceuticals, which would enable the combined company to sell more products to doctors and hospitals, according to James Molloy, Managing Director at Janney Montgomery Scott. Molloy explains why he believes the deal is a smart one for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.